Loading stock…

ArriVent BioPharma, Inc. (AVBP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ArriVent BioPharma, Inc.

AVBPMarket cap $0.74BPrice $15.1

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cancer therapies by licensing promising drug candidates from Chinese biotech firms and pushing them through U.S. clinical trials. Its lead lung cancer drug already beat expectations in early testing, betting big on cross-border innovation before big pharma catches on.

In Bastion Portfolios?

52W Return-23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)na–

Rev CAGR (3y)na–

Rev CAGR (5y)na–

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Marginna–

Net Income Marginna–

Free Cash Flow Marginna–

Debt

Net Debt/EBITDA2.14

Efficiency

ROE-53%1

ROA-49%1

Earnings Stabilityna–

GEAR+VERY WEAK1

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.07

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yieldna–

Dividend Yieldna–

Momentum

Short term

1 month return-51%1

3 month return-56%1

YTD return-25%2

Mid term

Price vs 52wHigh42%1

1 year return-22%2

Long term

3 year return-25%2

5 year return-25%2

Risk Shield

Price Risk

Beta1.32

Volatility85%1

Free Cash Flow

Free Cash Flow Marginna–

Free Cash Flow Yieldna–

Quality

ROCE-57%1

Earnings Stabilityna–

Net Debt/EBITDA2.14

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-51%1

3-month return-56%1

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high42%1

1-year return-22%2

3-year return-25%2

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -25% over five), behind 80% of the market.

It's down 22% over the past year, now 58% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-51%), over three months (-56%) and so far this year (-25%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ArriVent BioPharma, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-51%1

3-month return-56%1

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high42%1

1-year return-22%2

3-year return-25%2

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -25% over five), behind 80% of the market.

It's down 22% over the past year, now 58% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-51%), over three months (-56%) and so far this year (-25%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on ArriVent BioPharma, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community